These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 6895614)
1. CT monitoring of chemotherapeutic agent delivery after osmotic blood brain barrier disruption. Neuwelt EA Clin Neurosurg; 1981; 28():520-31. PubMed ID: 6895614 [No Abstract] [Full Text] [Related]
2. Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Neuwelt EA; Diehl JT; Vu LH; Hill SA; Michael AJ; Frenkel EP Ann Intern Med; 1981 Apr; 94(4 pt 1):449-54. PubMed ID: 6782926 [TBL] [Abstract][Full Text] [Related]
4. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Neuwelt EA; Rapoport SI Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and the blood-brain barrier. Blasberg RG Natl Cancer Inst Monogr; 1977 Dec; 46():19-27. PubMed ID: 349396 [No Abstract] [Full Text] [Related]
6. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors. Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316 [TBL] [Abstract][Full Text] [Related]
7. Intra-arterial chemotherapy following blood-brain barrier disruption in a patient with malignant glioma. Hill SA; Neuwelt EA J Neurosurg Nurs; 1982 Apr; 14(2):94-7. PubMed ID: 6811704 [No Abstract] [Full Text] [Related]
8. Osmotic blood-brain barrier disruption: a new means of increasing chemotherapeutic agent delivery. Neuwelt EA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Hill SA; Lewis SE; Ehle AL; Beyer CW; Moore RJ Trans Am Neurol Assoc; 1979; 104():256-60. PubMed ID: 121949 [No Abstract] [Full Text] [Related]
9. Amphotericin B and the blood-brain barrier to methotrexate. Barry DI; Paulson OB Neurosurgery; 1982 Feb; 10(2):224-6. PubMed ID: 7070618 [TBL] [Abstract][Full Text] [Related]
10. Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption. Neuwelt EA; Maravilla KR; Frenkel EP; Barnett P; Hill S; Moore RJ Neurosurgery; 1980 Jan; 6(1):49-56. PubMed ID: 6153461 [TBL] [Abstract][Full Text] [Related]
11. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Blasberg RG; Groothuis DR Semin Oncol; 1986 Mar; 13(1):70-82. PubMed ID: 3513317 [No Abstract] [Full Text] [Related]
15. Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Neuwelt EA; Frenkel EP; D'Agostino AN; Carney DN; Minna JD; Barnett PA; McCormick CI Cancer Res; 1985 Jun; 45(6):2827-33. PubMed ID: 2985254 [TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats. Cosolo W; Christophidis N Cancer Res; 1987 Dec; 47(23):6225-8. PubMed ID: 3119195 [TBL] [Abstract][Full Text] [Related]
19. Reversible osmotic blood-brain barrier disruption in humans: implications for the chemotherapy of malignant brain tumors. Neuwelt EA; Frenkel EP; Diehl J; Vu LH; Rapoport S; Hill S Neurosurgery; 1980 Jul; 7(1):44-52. PubMed ID: 6251399 [TBL] [Abstract][Full Text] [Related]
20. Re: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma. Goldstein DA; Tessler HH Am J Ophthalmol; 2007 Dec; 144(6):976; author reply 976. PubMed ID: 18036877 [No Abstract] [Full Text] [Related] [Next] [New Search]